Cargando…

Longitudinal DAT changes measured with [(18)F]FE-PE2I PET in patients with Parkinson’s disease; a validation study

BACKGROUND: Dopamine transporter (DAT) PET provides higher resolution than DAT SPECT and opportunity for integrated imaging with MRI. The radioligand [(18)F]FE-PE2I is highly selective for the DAT, and PET measurements with this radioligand have good reliability and repeatability in patients with no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerstens, V.S., Fazio, P., Sundgren, M., Brumberg, J., Halldin, C., Svenningsson, P., Varrone, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978841/ https://www.ncbi.nlm.nih.gov/pubmed/36822016 http://dx.doi.org/10.1016/j.nicl.2023.103347

Ejemplares similares

[(18)F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
por: Kerstens, Vera S., et al.
Publicado: (2023)

Simplified quantification of [(18)F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium
por: Brumberg, Joachim, et al.
Publicado: (2020)

Reliability of dopamine transporter PET measurements with [(18)F]FE-PE2I in patients with Parkinson’s disease
por: Kerstens, Vera S., et al.
Publicado: (2020)

High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort
por: Fazio, Patrik, et al.
Publicado: (2020)

Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [(18)F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
por: Schou, Magnus, et al.
Publicado: (2023)

PET Imaging of VMAT2 with the Novel Radioligand [(18)F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [(11)C]DTBZ and [(18)F]FE-DTBZ
por: Nag, Sangram, et al.
Publicado: (2021)

Sertraline treatment influences [(18)F]FE-PE2I PET imaging for Parkinsonism
por: Justesen, Thomas E. H., et al.
Publicado: (2023)

Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images
por: Rahmim, Arman, et al.
Publicado: (2017)

Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT—a clinical comparison
por: Jakobson Mo, Susanna, et al.
Publicado: (2018)

PET imaging of [(11)C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
por: Varnäs, Katarina, et al.
Publicado: (2018)

Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations
por: Fu, Jessie Fanglu, et al.
Publicado: (2019)

Development and validation of a novel dementia of Alzheimer's type (DAT) score based on metabolism FDG-PET imaging
por: Popuri, Karteek, et al.
Publicado: (2018)

Relation of 18-F-Dopa PET with hypokinesia-rigidity, tremor and freezing in Parkinson’s disease
por: Pikstra, Angelina R.A., et al.
Publicado: (2016)

[(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
por: Marner, Lisbeth, et al.
Publicado: (2022)

Correction: [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
por: Marner, Lisbeth, et al.
Publicado: (2023)

Fully Automated GMP-Compliant Synthesis of [(18)F]FE-PE2I
por: Bratteby, Klas, et al.
Publicado: (2021)

[ (18)F]PM‐PBB3‐PET Reveals Clinical and [ (18)F]FDG‐PET Mimics of 4‐Repeat Tauopathy Caused by Creutzfeld‐Jakob Disease
por: Schröter, Nils, et al.
Publicado: (2023)

Evaluation of the early-phase [(18)F]AV45 PET as an optimal surrogate of [(18)F]FDG PET in ageing and Alzheimer’s clinical syndrome
por: Vanhoutte, Matthieu, et al.
Publicado: (2021)

Validation of dynamic [(18)F]FE-PE2I PET for estimation of relative regional cerebral blood flow: a comparison with [(15)O]H(2)O PET
por: Jakobson Mo, Susanna, et al.
Publicado: (2022)

Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [(18)F]FMeNER-D(2)
por: Arakawa, Ryosuke, et al.
Publicado: (2019)

Decreased defluorination using the novel beta-cell imaging agent [(18)F]FE-DTBZ-d4 in pigs examined by PET
por: Jahan, Mahabuba, et al.
Publicado: (2011)

Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An (123)I-FP-CIT SPECT study
por: Joling, Merijn, et al.
Publicado: (2019)

Quantification of the purinergic P2X(7) receptor with [(11)C]SMW139 improves through correction for brain-penetrating radiometabolites
por: Brumberg, Joachim, et al.
Publicado: (2022)

Parkinson’s disease laterality: a (11)C-PE2I PET imaging study
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2020)

Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders
por: Stormezand, Gilles N., et al.
Publicado: (2020)

Novel Imaging Biomarkers for Huntington’s Disease and Other Hereditary Choreas
por: Fazio, Patrik, et al.
Publicado: (2018)

(18)F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus
por: Townley, Ryan A., et al.
Publicado: (2018)

Simplified and accessible [(18)F]F‐AraG synthesis procedure for preclinical PET
por: Högnäsbacka, Antonia A., et al.
Publicado: (2022)

Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [(18)F]FE-PE2I
por: Nogami, Tsuyoshi, et al.
Publicado: (2022)

Does Information from the Parkinson KinetiGraph™ (PKG) Influence the Neurologist’s Treatment Decisions?—An Observational Study in Routine Clinical Care of People with Parkinson’s Disease
por: Sundgren, Mathias, et al.
Publicado: (2021)

A resting-state fMRI pattern of spinocerebellar ataxia type 3 and comparison with (18)F-FDG PET
por: van der Horn, Harm J., et al.
Publicado: (2022)

Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases
por: Daerr, Sonja, et al.
Publicado: (2016)

Longitudinal [(18)F]FDG and [(13)N]NH(3) PET/CT imaging of brain and spinal cord in a canine hemisection spinal cord injury model
por: Zhang, Lijian, et al.
Publicado: (2021)

In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [(18)F]FEDAA1106
por: Takano, Akihiro, et al.
Publicado: (2013)

Negative DAT‐SPECT in Old Onset Parkinson's Disease: An Additional Pitfall?
por: Palermo, Giovanni, et al.
Publicado: (2022)

Selective dopaminergic vulnerability in Parkinson’s disease: new insights into the role of DAT
por: Harraz, Maged M.
Publicado: (2023)

PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [(18)F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain
por: Varnäs, Katarina, et al.
Publicado: (2023)

Differences in Striatal Metabolism in [(18)F]FDG PET in Parkinson’s Disease and Atypical Parkinsonism
por: Seiffert, Alexander P., et al.
Publicado: (2022)

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [(18)F]PF-06684511
por: Arakawa, Ryosuke, et al.
Publicado: (2020)

Arterial spin labeling versus (18)F-FDG-PET to identify mild cognitive impairment
por: Dolui, Sudipto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sku0n87ormb0nrfh6n7dotj13v